UNSPSC 51332204: Carpipramine dihydrochloride

This classification denotes an antipsychotic agent with the molecular formula C28H38N4O.2ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53X71X3I1W, chemically known as 1-(3-(10,11-dihydro-5h-dibenz(b,f)azepin-5-yl)propyl)-(1,4-bipiperidine)-4-carboxamide dihydrochloride monohydrate but more generally known as carpipramine dihydrochloride, which bears US NIH Compound Identifier 23476.

UNSPSC 51332204 Carpipramine dihydrochloride is a Commodity code that covers a specific antidepressant pharmaceutical product, but recent state and local procurement activity under this code does not reflect direct procurement of carpipramine. Instead, the opportunities posted show state and local governments buying naloxone (an opioid overdose reversal drug), safe drug deactivation systems, and broader generic multi-source pharmaceuticals and over-the-counter products through wholesaler networks and direct-to-manufacturer prescription programs. The mismatch between the code's nominal scope and actual recent solicitations suggests this code is either misapplied to broader pharmaceutical procurement or sees minimal specific activity for carpipramine itself. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state, local, and participating jurisdiction facilities).

Geographic activity centers on Florida, Texas, and Minnesota, with the multistate cooperative arrangement extending coverage to Oregon and other member jurisdictions. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026; due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) exploring direct-to-manufacturer prescription program capabilities, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026; due March 26, 2026) establishing multiple generic pharmaceutical and OTC product contracts through authorized wholesalers with awards effective July 1, 2026. The code shows little relevant recent activity for carpipramine specifically; procurement under related pharmaceutical codes or through state formulary and group purchasing organization channels would be more productive avenues for vendors in this market segment.